NORDIC BIOTECH K/S - CVR: 26290724

2022, DKK

12.06.2023

Bruttoresultat

Na.

Primær drift

-44.568'

Årets resultat

-44.572'

Aktiver

34.208'

Kortfristede aktiver

606'

Egenkapital

34.150'

Afkastningsgrad

-130 %

Soliditetsgrad

100 %

Likviditetsgrad

+500%

Resultat

12.06.2023

Årsrapport	2022 12.06.2023	2021 18.05.2022	2020 12.05.2021	2019 02.09.2020	2018 01.05.2019	2017 15.05.2018	2016 05.05.2017	2015 12.04.2016
Nettoomsætning
Resultat af primær drift	-44.568.000	-6.381.000	-1.354.000	13.005.000	-464.671.000	149.666.000	0	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	-1.256.000	0	1.360.000	0	-1.098.668.000	317.590.000
Finansielle indtægter	0	0	0	0	0	0	0	0
Finansieringsomkostninger	0	0	0	0	0	0	0	0
Andre finansielle omkostninger	-4.000	-6.000	-6.000	-8.000	-5.000	-20.000	-1.000	0
Resultat før skat	0	0	0	0	0	0	0	0
Resultat	-44.572.000	-6.387.000	-1.360.000	12.997.000	-464.676.000	149.646.000	-1.098.813.000	317.378.000
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

12.06.2023

Årsrapport	2022 12.06.2023	2021 18.05.2022	2020 12.05.2021	2019 02.09.2020	2018 01.05.2019	2017 15.05.2018	2016 05.05.2017	2015 12.04.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	0	0	0	0	0	0	0	0
Likvider	606.000	734.000	858.000	1.036.000	1.183.000	41.000	24.000	22.000
Kortfristede aktiver	606.000	734.000	858.000	1.036.000	1.183.000	41.000	24.000	22.000
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0
Finansielle anlægsaktiver	33.600.000	78.050.000	84.312.000	85.568.000	72.401.000	538.394.000	2.267.263.000	3.365.931.000
Materielle aktiver	0	0	0	0	0	0	0	0
Langfristede aktiver	33.600.000	78.050.000	84.312.000	85.568.000	72.401.000	538.394.000	2.267.263.000	3.365.931.000
Aktiver	34.208.000	78.784.000	85.170.000	86.604.000	73.584.000	538.435.000	2.267.287.000	3.365.953.000

Aktiver

12.06.2023

Passiver

12.06.2023

Årsrapport	2022 12.06.2023	2021 18.05.2022	2020 12.05.2021	2019 02.09.2020	2018 01.05.2019	2017 15.05.2018	2016 05.05.2017	2015 12.04.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	34.150.000	78.722.000	85.109.000	86.469.000	73.472.000	538.148.000	2.266.804.000	3.365.617.000
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0
Kortfristede forpligtelser	58.000	63.000	61.000	135.000	112.000	287.000	0	190.000
Gældsforpligtelser	58.000	63.000	61.000	135.000	112.000	287.000	483.000	336.000
Forpligtelser	58.000	63.000	61.000	135.000	112.000	287.000	483.000	336.000
Passiver	34.208.000	78.784.000	85.170.000	86.604.000	73.584.000	538.435.000	2.267.287.000	3.365.953.000

Passiver

12.06.2023

Nøgletal

12.06.2023

Årsrapport	2022 12.06.2023	2021 18.05.2022	2020 12.05.2021	2019 02.09.2020	2018 01.05.2019	2017 15.05.2018	2016 05.05.2017	2015 12.04.2016
Afkastningsgrad	-130,3 %	-8,1 %	-1,6 %	15,0 %	-631,5 %	27,8 %	Na.	Na.
Dækningsgrad
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-130,5 %	-8,1 %	-1,6 %	15,0 %	-632,5 %	27,8 %	-48,5 %	9,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Soliditestgrad	99,8 %	99,9 %	99,9 %	99,8 %	99,8 %	99,9 %	100,0 %	100,0 %
Likviditetsgrad	1.044,8 %	1.165,1 %	1.406,6 %	767,4 %	1.056,3 %	14,3 %	Na.	11,6 %

Resultat

12.06.2023

Gæld

12.06.2023

Årsrapport

12.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 12.06.2023)

Information om virksomhedens regnskabsklasse:The annual report of Nordic Biotech K/S for 2022 has been prepared in accordance with the provisions applying to reporting class B enterprises under the Danish Financial Statements ActPursuant to Section 110(1) of the Danish Financial Statements Act the Limited Partnership has not prepared consolidated financial statements

Beretning

12.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-05-30

Ledelsespåtegning:Statement by the General Partner

Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertaintiesThe Limited Partnership measures all of its investments at fair value in accordance with the valuation guidelines recommended by Invest Europe (currently the IPEV valuation guidelines) The valuations in the annual report are subject to inherent uncertainty because they among others are based on assumptions that are to a wide extent judgmentalWhile the Limited Partnership's investment in Forward Pharma A/S has been valued based on the stock price of publicly traded ADSs representing shares in Forward Pharma A/S the Limited Partnership's investment in Aditech Pharma AG has been determined using commonly applied valuation techniques for unquoted entities The ADSs in Forward Pharma A/S have been delisted from Nasdaq New York on 28 December 2022 and now trades on an over-the-counter market Aditech Pharma AG is in liquidation and will not receive any further income from Forward Pharma or other sourches Hence the valuation is not uncertain

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The annual report has been prepared in accordance with the Danish Financial Statements Act

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Principal activitiesThe Limited Partnership is a venture capital Limited Partnership established in 2001 and focusing on early stage investments restructurings and spin offs in the biotech industryAt 31 December 2022 the portfolio of the Limited Partnership included three investments not yet disposed of by the Limited Partnership These are further described below